Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $26.35 USD
Change Today -1.37 / -4.94%
Volume 150.3K
OCUL On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

ocular therapeutix inc (OCUL) Snapshot

Open
$27.52
Previous Close
$27.72
Day High
$27.68
Day Low
$26.24
52 Week High
03/25/15 - $44.19
52 Week Low
07/31/14 - $11.90
Market Cap
564.3M
Average Volume 10 Days
702.7K
EPS TTM
$-5.41
Shares Outstanding
21.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OCULAR THERAPEUTIX INC (OCUL)

Related News

No related news articles were found.

ocular therapeutix inc (OCUL) Related Businessweek News

No Related Businessweek News Found

ocular therapeutix inc (OCUL) Details

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for eye diseases and conditions using its proprietary hydrogel platform technology in the United States. It markets ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions during cataract surgery. The company is involved in developing OTX-DP that is in Phase III clinical trials for post-surgical ocular inflammation and pain; and is in Phase II clinical trials for the treatment of inflammatory dry eye disease, as well as that has completed Phase II clinical trials for the treatment of allergic conjunctivitis. It is also developing OTX-TP, which is in Phase IIb clinical trials for glaucoma and ocular hypertension; OTX-MP product candidate that has completed Phase I clinical trials for the treatment of ocular infection indication; and Anti-VEGF hydrogel depot, an injectable hydrogel depot that is in preclinical studies. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.

74 Employees
Last Reported Date: 03/20/15
Founded in 2006

ocular therapeutix inc (OCUL) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $254.9K
Chief Operating Officer
Total Annual Compensation: $362.5K
Executive Vice President of Clinical, Regulat...
Total Annual Compensation: $321.5K
Compensation as of Fiscal Year 2013.

ocular therapeutix inc (OCUL) Key Developments

Ocular Therapeutix, Inc. - Special Call

To discuss the results of the Phase 3 clinical trials evaluating OTX-DP for the treatment of post-surgical inflammation and pain

Ocular Therapeutix Announces Earnings Results for the Fourth Quarter of 2014

Ocular Therapeutix announced earnings results for the fourth quarter of 2014. For the period, the company’s net loss totaled $8.0 million, or $0.37 per share, compared to a net loss of $3.5 million, or $1.32 per share a year earlier. Revenues totaled $500,000, topping the consensus of $200,000.

Ocular Therapeutix, Inc. Reports Positive Topline Clinical Data for the First of Two Phase 3 Clinical Trials Evaluating OTX-DP for the Treatment of Post-Surgical Ocular Inflammation and Pain

Ocular Therapeutix, Inc. announced positive topline data from the first of two Phase 3 clinical trials evaluating the safety and efficacy of its lead product candidate, OTX-DP (Sustained Release Dexamethasone), for the treatment of ocular inflammation and pain following cataract surgery. The Phase 3a study, which enrolled 247 patients, met both primary efficacy measures, achieving a statistically significant improvement in the reduction of inflammatory cells and pain. 33.7% of OTX-DP-treated patients showed an absence of inflammatory cells in the anterior chamber of the study eye on day 14 following drug product insertion, compared to 14.6% of those receiving placebo vehicle control punctum plug (p=0.0015). In addition, 76.1% of patients receiving OTX-DP reported absence of pain in the study eye on day 8 following insertion of the drug product, compared to 36.1% of those receiving placebo vehicle control punctum plug (p< 0.0001). Ocular is continuing to analyze the safety findings from the clinical trial. OTX-DP is a product candidate placed in the canaliculus and designed to deliver dexamethasone to the ocular surface for approximately four weeks. Following treatment, OTX-DP resorbs and exits the nasolacrimal system without need for removal. Two prospective, multicenter, randomized, parallel-arm, double-masked, vehicle-controlled Phase 3 clinical trials, referred to as the Phase 3a and Phase 3b clinical trials, were completed with a total of 487 patients (247 patients in Phase 3a and 240 in Phase 3b) undergoing unilateral clear corneal cataract surgery. Patients were randomized 2:1 to receive either OTX-DP or a placebo vehicle control punctum plug without active drug. Both primary efficacy measures, differences in the proportion of patients in each treatment group with absence of cells in the anterior chamber of the study eye, as measured using slit lamp examination, at day 14 and absence of pain, as graded by a patient-reported score of zero on a scale from zero to ten, at day 8 were recorded at each study visit. Secondary efficacy measures were absence of flare in the anterior chamber of the study eye at each evaluation date and absence of inflammatory cells in the anterior chamber of the study eye and absence of pain in the study eye at each evaluation date other than the day used for the primary efficacy measure. Topline data from the Phase 3b clinical trial are expected to be announced by the end of March. If the Company obtains favorable aggregate results for both the Phase 3a and Phase 3b clinical trials, the Company expects to submit a New Drug Application (NDA) for OTX-DP for post-surgical ocular inflammation and pain in the second quarter of 2015. The company believes that OTX-DP is the first sustained release drug-eluting corticosteroid punctum plug to enter and complete Phase 3 clinical trials. Ocular inflammation and pain are common side effects following ophthalmic surgery. Physicians prescribe anti-inflammatory drugs, such as corticosteroids, as the standard of care. If left untreated, inflammation of the eye may result in further ocular complications, including scarring and vision loss. Market Scope estimates approximately 5 million ocular surgeries will be performed in the United States in 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCUL:US $26.35 USD -1.37

OCUL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OCUL.
View Industry Companies
 

Industry Analysis

OCUL

Industry Average

Valuation OCUL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 726.7x
Price/Book 9.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 614.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCULAR THERAPEUTIX INC, please visit www.ocutx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.